FDA Resubmission is Positive for Lipocine (LPCN), Underscores Good Execution, Reiterate Overweight - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $3.00 price target on Lipocine Inc (NASDAQ: LPCN), following announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
